SNAP Biosciences and Monarch Therapeutics announce a licensing deal for advanced NK cell therapies using small molecule adaptors.
Quiver AI Summary
SNAP Biosciences, a subsidiary of Coeptis Therapeutics Holdings, has entered into a licensing agreement with Monarch Therapeutics to develop and commercialize its Snap-Car NK cell therapy platform for oncology applications. This partnership allows SNAP Biosciences to utilize Monarch's novel small-molecule adaptor technology, enhancing the Snap-Car platform's precision and modularity by enabling NK cells to target multiple tumor antigens and adjust their activity in real-time. The CEOs of both companies expressed excitement about the collaboration's potential to provide advanced therapies for patients with difficult-to-treat cancers. Monarch will receive an upfront licensing fee, milestone payments, and royalties from future sales as part of the agreement.
Potential Positives
- SNAP Biosciences has entered a licensing agreement with Monarch Therapeutics, granting access to innovative small molecule adaptor technology that enhances their proprietary Snap-Car NK cell therapy platform.
- This collaboration aims to advance more potent and flexible NK therapies, which could improve treatment outcomes for patients with difficult-to-treat cancers.
- The integration of Monarch’s technology allows SNAP-CAR cells to target multiple tumor antigens simultaneously and modulate their activity in real-time, addressing challenges of tumor heterogeneity and antigen escape.
- The agreement also includes potential future financial benefits for Monarch through milestone payments and royalties on net sales, indicating a structured business relationship that may foster further development opportunities.
Potential Negatives
- The licensing agreement with Monarch Therapeutics may indicate that SNAP Biosciences lacks complete control over its proprietary technology, as they are relying on a partnership for development and commercialization.
- SNAP Biosciences may face increased pressure to deliver results under the terms of the licensing agreement, including milestone payments and royalties, which could impact profitability.
- The reliance on external technology might raise concerns about the long-term viability and competitiveness of SNAP's proprietary Snap-Car NK cell therapy platform.
FAQ
What is the Snap-Car NK cell therapy platform?
The Snap-Car NK cell therapy platform is a "universal" CAR cell therapy developed by SNAP Biosciences to target multiple tumor antigens.
How does Monarch Therapeutics' adaptor technology enhance cell therapy?
Monarch's small molecule adaptor technology allows for more precise and flexible targeting of multiple antigens in cell therapies.
What benefits does the licensing agreement provide for SNAP Biosciences?
The agreement grants access to advanced adaptor technology, improving the functionality and effectiveness of the Snap-Car NK cell therapies.
What is the focus of Coeptis Therapeutics Holdings, Inc.?
Coeptis is focused on developing innovative cell therapy platforms for cancer, autoimmune diseases, and infectious diseases.
How can the Snap-Car NK cell therapy address tumor heterogeneity?
This therapy integrates modular adaptors, allowing real-time targeting of multiple tumor antigens to combat tumor variability effectively.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$COEP Hedge Fund Activity
We have seen 0 institutional investors add shares of $COEP stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TOWER RESEARCH CAPITAL LLC (TRC) removed 479 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $2,634
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WEXFORD, Pa. and PRINCETON, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SNAP Biosciences, Inc a majority-owned subsidiary of Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) and Monarch Therapeutics Inc., a biotechnology company pioneering next-generation immunotherapies, today announced a licensing agreement to enable the development and commercialization of SNAP Biosciences’ proprietary Snap-Car NK cell therapy platform in oncology using Monarch’s small molecule adaptor technology.
This agreement grants SNAP Biosciences access to Monarch’s novel small-molecule adaptor-based technology platform, significantly broadening the functionality of the Snap-Car universal CAR-based receptor platform. Monarch’s ground-breaking small molecule approach, invented by Monarch’s scientific co-founders Drs. Jason Lohmueller and Alexander Deiters, enables SNAP-CAR cells to be directed by small molecule-based adaptors, enhancing the system’s precision, flexibility, and modular potential across diverse therapeutic areas.
“This agreement underscores the growing recognition of our adaptor technology as a transformative tool for cell therapy,” said Christopher Potts, CEO of Monarch Therapeutics. “We are thrilled to have the team at SNAP Bioscience bring this exciting technology to patients with a new generation of NK therapies that have the potential to be both highly targeted and curative.”
The Snap-Car NK cells represent a promising platform technology in the cell therapy landscape. By integrating Monarch’s small molecule adaptors, these therapies can now be engineered to simultaneously target multiple tumor antigens and modulate their activity in real-time, with an improved manufacturing and regulatory pathway. This advanced functionality offers a significant leap forward in addressing tumor heterogeneity and challenges associated with antigen escape commonly encountered in oncology.
“We are thrilled to incorporate this innovative adaptor technology into our Snap-Car NK platform,” said Dave Mehalick, CEO at Coeptis Therapeutics Holdings, inc. “This collaboration positions us to advance more potent, flexible, and scalable NK therapies aimed at transforming outcomes for patients with difficult-to-treat cancers.”
Under the terms of the agreement, Monarch will receive an upfront licensing payment and is eligible for future development milestone payments, as well as royalties on net sales.
About Monarch Therapeutics Inc.
Monarch Therapeutics is a pre-clinical stage biotechnology company focused on developing next-generation immunotherapies. The company’s proprietary adaptor platform enables precise, programmable control of cell-based therapies, expanding their reach and dynamic disease targeting across a broad range of therapeutic areas. With a focus on solid tumors, Monarch Therapeutics implements its adaptor platform to drive universal CAR-T cell therapies with leading tunability, mutli-antigen targeting, and control. For more information, visit https://monarchtherapeutics.com/
About SNAP Biosciences Inc.
SNAP Biosciences, Inc is a majority-owned subsidiary and one of the biopharmaceutical divisions of Coeptis Therapeutics Holdings, Inc. SNAP Bioscience’s is focusing on the development of Snap-Car, a "universal" CAR (chimeric antigen receptor) cell therapy, that uses a SNAP molecule to connect a CAR to tumor cells. This allows for programmable antigen targeting through co-administered antibodies, providing flexibility in targeting multiple antigens and indications. For more information, visit https://snapbioscience.com
About Coeptis Therapeutics Holdings, Inc
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
Coeptis’ therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Coeptis is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, Coeptis has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, Coeptis is dedicated to advancing its mission within the regulatory framework set forth by the Food and Drug Administration, ensuring that all activities align with the highest standards of compliance and patient care. For more information on Coeptis and its lines of business, visit https://coeptistx.com
Contacts
[email protected]
